Roivant Sciences Ltd. (ROIV) has 20 tenedores institucionales e internos conocidos registrados. El mayor tenedor es Dexcel Pharma Technologies Ltd. con 102,849,443 acciones. Otros tenedores destacados incluyen Oren Dan y SVF Investments (UK) Ltd.
En los últimos 12 meses, los internos han realizado 67 transacciones en ROIV acciones — 3 compras (valoradas en $5.75M) y 34 ventas (valoradas en $204.8M). Las ventas internas han superado las compras durante este período.
ROIV Participación de Insiders
Principal Titular
Dexcel Pharma Technologies Ltd.
102,849,443 acciones
Compras (12 meses)
3
$5.75M valor
Ventas (12 meses)
34
$204.8M valor
Actividad de Transacciones (12 meses)
Principales Titulares Internos
| # |
Nombre |
Cargo |
Acciones en Propiedad |
Última Declaración |
Tamaño Relativo |
| 1 |
Dexcel Pharma Technologies Ltd. |
Director |
102,849,443 |
2022-11-14 |
|
| 2 |
Oren Dan |
Director |
98,840,843 |
2022-04-26 |
|
| 3 |
Svf Investments (uk) Ltd |
10 Percent Owner |
73,031,667 |
2023-10-02 |
|
| 4 |
Sumitomo Chemical Co., Ltd. |
10 Percent Owner |
71,251,083 |
2023-06-26 |
|
| 5 |
Ramaswamy Vivek |
10 Percent Owner |
37,861,115 |
2025-06-23 |
|
| 6 |
Sukhatme Mayukh |
President & CIO |
18,677,617 |
2026-04-01 |
|
| 7 |
Gline Matthew |
CEO |
17,025,890 |
2026-04-01 |
|
| 8 |
Manchester Keith S |
Director |
15,928,113 |
2026-02-13 |
|
| 9 |
Qvt Financial Lp |
Other: Director By Deputization |
15,928,113 |
2026-02-13 |
|
| 10 |
Gold Daniel Allen |
Director |
15,928,113 |
2026-02-13 |
|
| 11 |
Torti Frank |
President and Vant Chair |
13,576,512 |
2026-04-02 |
|
| 12 |
Venker Eric |
President & Immunovant CEO |
1,647,546 |
2026-03-19 |
|
| 13 |
Viking Global Performance Llc |
10 Percent Owner |
641,010 |
2023-06-26 |
|
| 14 |
Viking Global Investors Lp |
10 Percent Owner |
641,010 |
2023-06-26 |
|
| 15 |
Pulik Richard |
CFO |
236,867 |
2026-03-24 |
|
| 16 |
Kumar Rakhi |
Chief Accounting Officer |
162,306 |
2025-02-24 |
|
| 17 |
Oren Ilan |
Director |
119,428 |
2026-01-22 |
|
| 18 |
Momtazee James C |
Director |
109,030 |
2026-01-22 |
|
| 19 |
Humes Jennifer |
Chief Accounting Officer |
97,729 |
2026-03-24 |
|
| 20 |
Lo Andrew |
Director |
52,142 |
2022-09-19 |
|
Transacciones Recientes (últimos 12 meses)
| Fecha |
Nombre |
Cargo |
Tipo |
Acciones |
Precio |
Valor |
| 2026-03-31 |
Torti Frank |
President and Vant Chair |
Retención Fiscal de RSU |
160,035 |
$27.70 |
$4.43M |
| 2026-03-31 |
Gline Matthew |
CEO |
Retención Fiscal de RSU |
304,684 |
$27.70 |
$8.44M |
| 2026-03-30 |
Gline Matthew |
CEO |
Ejercicio de Opciones (Venta) |
2,178,150 |
- |
- |
| 2026-03-31 |
Sukhatme Mayukh |
President & CIO |
Retención Fiscal de RSU |
187,512 |
$27.70 |
$5.19M |
| 2026-03-30 |
Sukhatme Mayukh |
President & CIO |
Ejercicio de Opciones (Venta) |
1,306,889 |
- |
- |
| 2026-03-26 |
Fitzgerald Meghan |
Director |
Venta Informativa |
70,000 |
$27.45 |
$1.92M |
| 2026-03-20 |
Humes Jennifer |
Chief Accounting Officer |
Retención Fiscal de RSU |
14,526 |
$27.70 |
$402.37K |
| 2026-03-20 |
Pulik Richard |
CFO |
Retención Fiscal de RSU |
1,546 |
$27.70 |
$42.82K |
| 2026-03-17 |
Venker Eric |
President & Immunovant CEO |
Venta Informativa |
200,000 |
$28.24 |
$5.65M |
| 2026-03-16 |
Epperly Melissa B, |
Director |
Venta Informativa |
41,861 |
$28.68 |
$1.2M |
| 2026-02-20 |
Pulik Richard |
CFO |
Retención Fiscal de RSU |
1,000 |
$27.15 |
$27.15K |
| 2026-02-20 |
Venker Eric |
President & Immunovant CEO |
Retención Fiscal de RSU |
7,051 |
$27.15 |
$191.43K |
| 2026-02-23 |
Torti Frank |
President and Vant Chair |
Ejercicio de Opciones (Venta) |
587,390 |
$3.85 |
$2.26M |
| 2026-02-20 |
Torti Frank |
President and Vant Chair |
Ejercicio de Opciones (Venta) |
1,012,610 |
$3.85 |
$3.9M |
| 2026-02-19 |
Torti Frank |
President and Vant Chair |
Ejercicio de Opciones (Venta) |
1,400,000 |
$3.85 |
$5.39M |
| 2026-02-13 |
Venker Eric |
President & Immunovant CEO |
Venta Informativa |
200,000 |
$26.49 |
$5.3M |
| 2026-02-13 |
Gold Daniel Allen |
Director |
Venta Informativa |
225,000 |
$26.50 |
$5.96M |
| 2026-02-12 |
Gold Daniel Allen |
Director |
Venta Informativa |
275,000 |
$26.76 |
$7.36M |
| 2026-02-11 |
Gold Daniel Allen |
Director |
Venta Informativa |
425,000 |
$26.67 |
$11.33M |
| 2026-02-13 |
Qvt Financial Lp |
Other: Director By Deputization |
Venta Informativa |
225,000 |
$26.50 |
$5.96M |
| 2026-02-12 |
Qvt Financial Lp |
Other: Director By Deputization |
Venta Informativa |
275,000 |
$26.76 |
$7.36M |
| 2026-02-11 |
Qvt Financial Lp |
Other: Director By Deputization |
Venta Informativa |
425,000 |
$26.67 |
$11.33M |
| 2026-02-13 |
Manchester Keith S |
Director |
Venta Informativa |
225,000 |
$26.50 |
$5.96M |
| 2026-02-12 |
Manchester Keith S |
Director |
Venta Informativa |
275,000 |
$26.76 |
$7.36M |
| 2026-02-11 |
Manchester Keith S |
Director |
Venta Informativa |
425,000 |
$26.67 |
$11.33M |
